구자승 (연세대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문, 상위피인용논문

조회1,722

연세대학교 의과대학

CV File 20 kb

Progr Lipid Res, Volume 69, January 2018, Pages 11-20, https://doi.org/10.1016/j.plipres.2017.11.002 Adipocyte biology in breast cancer: From silent bystander to active facilitator

Junjeong Choi^a, Yoon Jin Cha^b, Ja Seung Koo^b^,*

^aCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea
^b Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea

^*Corresponding author

Abstract

Adipocytes account for the largest proportion among the cells that comprise breast tissue; therefore, they are considered to be a critical cell type in the tumor microenvironment of breast cancer. In breast cancer, adipocytes are not only found adjacent to cancer cells, but they also play an active role in the entire process of cancer development, progression, metastasis, and treatment response. Factors including the secretion of adipokines such as leptin and adiponectin, as well as autotaxin, interleukin 6, tumor necrosis factor alpha, and hepatic growth factor, metabolic remodeling that supports the growth of breast cancer by transfer of fatty acids to increase mitochondrial β-oxidation, extracellular matrix remodeling and endotrophin production from type IV collagen, and cancer-associated fibroblast phenotype changes have all been implicated in this comprehensive process. Moreover, adipocytes may act as obstacles to therapy, as they are involved in mechanisms of resistance against various breast cancer treatments. Adipose tissues may also be a reservoir for dormant tumor cells during postsurgical autologous fat grafting. Thus, adipocytes, and the processes and pathways in which they are involved, could be effective therapeutic targets for breast cancer. In this review, we focus on the current understanding of adipocyte biology as it affects breast cancer.

Keywords : Adipocyte; Breast cancer; Tumor-stroma interaction

논문정보

형식Review Paper
게재일2018년 01월 (BRIC 등록일 2018-02-12)
연구진국내 연구진
분야 의약학 > 종양의학
피인용횟수60회 이상 인용된 논문 (상위피인용논문 등록일 2021-05-03)

댓글 작성 로그인

CV 열람하기

연락처 보기